Cargando…
MON-358 Hypercalcemia During Teriparatide Therapy
Background: Teriparatide (TPTD) is a recombinant PTH analog used as an anabolic agent in the treatment of osteoporosis that stimulates bone formation and activates bone remodeling. The most common side effects are nausea, vomiting, hypertension and dizziness. Transient hypercalcemia is a known adver...
Autores principales: | Milosavljevic, Jovan, Thomas, Asha Mary |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207921/ http://dx.doi.org/10.1210/jendso/bvaa046.1112 |
Ejemplares similares
-
SAT-505 A Rare Case of Teriparatide Induced Persistent Hypercalcemia
por: Sistla, Divya, et al.
Publicado: (2019) -
SAT-358 Hypercalcemia-Induced Altered Mental Status as the Primary Manifestation of Classic Hodgkin Lymphoma
por: Modarressi, Taher, et al.
Publicado: (2020) -
MON-340 Isolated Extrapulmonary Sarcoidosis Presenting as Symptomatic Hypercalcemia
por: Swami, Janya
Publicado: (2020) -
MON-343 The Mystery of Recurrent PTH-Independent Hypercalcemia with Severe Hypophosphatemia
por: Shaikh, Bilal, et al.
Publicado: (2020) -
MON-335 Bisphosphonate and Denosumab Refractory Hypercalcemia of Malignancy: What Else Is at Play?
por: Patel, Reshma, et al.
Publicado: (2020)